> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Joint Panel Nixes Nektar’s Back Pain Drug
- URL: https://www.fdaweb.com/joint-panel-nixes-nektars-back-pain-drug/
- Published: 2020-01-15T12:00:00.000Z
- Updated: 2026-09-14T15:58:47.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5145852

FDA’s Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee has voted 27 to 0 to not recommend approval of Nektar Therapeutics’ oxycodegol for chronic low back pain. Based on the panel vote, the company said it would withdraw the NDA and stop further investment in the oxycodegol development program. During the joint deliberation, panel members questioned whether the data supported the product’s safety and efficacy. They also cited concerns about liver toxicity, and that not enough data about oxycodegol’s abuse potential was in the submission.